Aadel A Chaudhuri
Overview
Explore the profile of Aadel A Chaudhuri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
6738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walls G, Pellini B, Chaudhuri A
J Liq Biopsy
. 2025 Mar;
6:100160.
PMID: 40027308
Locally advanced non-small cell lung cancer (NSCLC) is a highly diverse disease in terms of its histology, staging and molecular biology, yet chemoradiation treatment paradigms are currently not individualized for...
2.
Szymanski J, Chauhan P, Chaudhuri A
Clin Cancer Res
. 2025 Jan;
PMID: 39879112
LINE-1 retrotransposons, comprising 17% of the genome, drive cancer instability through hypomethylation. The DIAMOND assay, targeting LINE-1 hypomethylation with bisulfite sequencing of cell free DNA, achieved AUCs of 88% to...
3.
Andrews J, Andrews J, Kim Y, Horjeti E, Arafa A, Gunn H, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39820657
Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong ADT-free survival or progression-free survival (PFS) in patients with metachronous oligometastatic prostate cancer (omCSPC)...
4.
Hashmi A, Greiner L, Chauhan P, Szymanski J, Park S, Olivier K, et al.
Hematol Oncol Clin North Am
. 2024 Dec;
39(2):257-268.
PMID: 39732580
Circulating tumor DNA (ctDNA) is emerging as a transformative biomarker in the management of non-small cell lung cancer (NSCLC). This review focuses on its role in detecting minimal residual disease...
5.
Aird K, Chaudhuri A, Guerriero J, Gur-Cohen S, Izar B, Jenkins B, et al.
Cancer Discov
. 2024 Dec;
14(12):2346-2351.
PMID: 39618282
No abstract available.
6.
Chauhan P, Alahi I, Sinha S, Ledet E, Mueller R, Linford J, et al.
Clin Cancer Res
. 2024 Aug;
31(1):151-163.
PMID: 39177583
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning...
7.
Sundby R, Szymanski J, Pan A, Jones P, Mahmood S, Reid O, et al.
Clin Cancer Res
. 2024 Aug;
30(19):4363-4376.
PMID: 39093127
Purpose: Early detection of neurofibromatosis type 1 (NF1)-associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we describe...
8.
Gentzler R, Guittar J, Mitra A, Iams W, Driessen T, Schwind R, et al.
Oncol Ther
. 2024 Jul;
12(3):509-524.
PMID: 39037536
Introduction: A dynamic molecular biomarker that can identify early efficacy of immune checkpoint inhibitor (ICI) therapy remains an unmet clinical need. Here we evaluate if a novel circulating tumor DNA...
9.
Semenkovich N, Agarwal G, Chaudhuri A
JAMA Oncol
. 2024 Jun;
10(8):1023-1024.
PMID: 38935353
No abstract available.
10.
Azad T, Nanjo S, Jin M, Chabon J, Kurtz D, Chaudhuri A, et al.
NPJ Precis Oncol
. 2024 May;
8(1):121.
PMID: 38806586
Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of the central nervous system. We applied a lung cancer-specific sequencing panel (CAPP-Seq) to 81...